TriMaximize: A study of a triple therapy inhaler for asthma
Part of Immune system & allergy, Lungs & breathing clinical trials.
This study is looking at how well a triple therapy inhaler (Trimbow®) works for people with asthma, including those who also have COPD. It aims to see if starting this treatment helps control symptoms and improve quality of life in everyday medical practice.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with asthma (you may also have COPD).
- Your doctor has decided to start you on the triple therapy inhaler Trimbow® (medium or high strength) for your asthma.
- You are willing to let the study use your anonymous medical information.
- You have not taken part in another clinical trial in the last 30 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a triple-inhaler called Trimbow for people whose asthma is not well controlled despite using other inhalers. The goal is to see if switching to Trimbow helps reduce asthma attacks and improve day-to-day breathing.
This study tests if using a small smart device with your Trimbow inhaler helps you use it correctly and take it as prescribed. It is for people with asthma who already use Trimbow.
This study compares a three-in-one inhaler (ICS/LABA/LAMA) to a two-in-one inhaler (ICS/LABA) for adults whose asthma is not well-controlled despite using a standard two-in-one inhaler. The goal is to see if the triple inhaler improves asthma control better.
This trial tests whether stepping up to either a higher dose of inhaled steroid/long-acting bronchodilator or a special fine-particle triple therapy (which includes an extra medication) can improve small-airway health in people whose asthma is still not well controlled on a medium-dose combination.
This study tests an investigational drug to see if it can improve asthma control in people whose asthma is not well managed with current treatments. It may help reduce symptoms and improve lung function.
This study tests a new combination inhaler (fluticasone propionate and albuterol) for people with asthma age 12 and older. It helps see if this inhaler works better than a placebo in controlling asthma symptoms and preventing attacks.
Hear when a new Asthma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.